A practical compliance session covering 21 CFR Part 11, EU GMP Annex 11, ALCOA+ data integrity principles, electronic signature requirements, hybrid documentation systems, and inspection-readiness for digital records environments.
Includes live access & recording
The pharmaceutical industry's transition from paper to electronic documentation has fundamentally changed how manufacturers create, review, approve, and archive GMP records. Yet many organizations discover that implementing an electronic batch record system is only the first step — managing those systems under continuous FDA and EU GMP scrutiny while maintaining absolute data integrity is an ongoing, high-stakes operational challenge.
This practical webinar goes beyond the basics of what digital batch records are and dives into how to govern them correctly. Topics include 21 CFR Part 11 and EU GMP Annex 11 compliance requirements, audit trail management, electronic signature controls, hybrid documentation management, and the specific documentation practices that FDA and EMA inspectors scrutinize during site visits.
Participants leave with actionable frameworks for building a documentation management program that meets both FDA and EU GMP requirements while remaining operationally practical — including how to detect and remediate data integrity gaps before they become inspection findings.
Data integrity deficiencies remain among the most cited categories in FDA Warning Letters and EU GMP non-compliance reports. The underlying cause is rarely deliberate fraud — it is most often inadequate system design, poor procedure governance, and misunderstood regulatory requirements for electronic records and audit trails.
Organizations that transition to digital batch records without a rigorous compliance framework frequently inherit new categories of data integrity risk. A paper record that has been altered is visible; a manipulated electronic record in a poorly controlled system may be invisible without properly configured audit trail software.
This webinar equips participants with the regulatory knowledge and practical tools to close the gap between having a digital documentation system and operating one that is fully 21 CFR Part 11 and EU GMP Annex 11 compliant — and inspection-ready.
This 90-minute session delivers the regulatory knowledge and practical compliance tools needed to govern digital batch records and GMP documentation with full data integrity across FDA and EU GMP frameworks.
Apply the full set of 21 CFR Part 11 requirements — including access controls, audit trails, system validation, and electronic signature requirements — to your current documentation systems.
Align your electronic records management approach with EU GMP Annex 11 and EMA data integrity guidance, including Annex 11 Chapter 7, 9, and 12 controls.
Implement ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, Available) across both electronic and hybrid documentation environments.
Manage hybrid documentation systems (paper and electronic coexisting) in a way that satisfies both FDA and EU GMP requirements without creating documentation control gaps.
Configure audit trail review programs that detect unauthorized changes, data deletions, backdated entries, and other data integrity risks before they become inspection findings.
Conduct pre-inspection self-assessments of your digital documentation program against current FDA and EMA inspection expectations and data integrity guidance documents.
Four core compliance dimensions every pharmaceutical organization must master to safely operate digital documentation systems under FDA and EU GMP oversight.
A side-by-side comparison of FDA and EU GMP electronic records requirements — where they converge, where they diverge, and how to build a single documentation governance program that satisfies both simultaneously.
What your audit trail must capture, how often it must be reviewed, who must review it, and what constitutes a compliant audit trail review program versus a form-filling exercise that provides no real data integrity protection.
The exact legal, regulatory, and technical requirements for electronic signatures under 21 CFR Part 11 and EU GMP — including when a click-to-approve constitutes a compliant signature versus when it does not.
How FDA and EMA inspectors assess data integrity during site visits — the specific questions they ask, the system walks they request, the records they examine, and the red flags that trigger escalated scrutiny.
A focused, practical curriculum addressing the most critical compliance and governance challenges in pharmaceutical digital documentation management.
21 CFR Part 11 requirements for electronic records and electronic signatures — scope, applicability, and current FDA enforcement posture
EU GMP Annex 11 compliance — computerized systems, access controls, data storage, printout controls, and audit trail requirements
ALCOA+ data integrity principles applied to digital batch records — implementation across EBR systems and supporting QMS platforms
Hybrid documentation management — governing paper and electronic records in parallel without creating data integrity gaps or chain-of-custody breaks
Audit trail design, configuration, and periodic review programs — what to capture, how to review, and how to document the review
Electronic signature controls — legal binding requirements, manifestation of signature, and common implementation deficiencies
Computer system validation (CSV) under GAMP 5 and FDA/EU expectations — validation lifecycle, risk categorization, and ongoing monitoring
Data backup, disaster recovery, and long-term archival requirements for electronic GMP records under FDA and EU GMP frameworks
Managing documentation during system migrations, upgrades, and vendor transitions without compromising record integrity or GMP traceability
Data integrity risk assessments — identifying vulnerabilities in existing systems, prioritizing remediation, and documenting corrective actions
FDA and EMA inspection expectations for digital documentation — what investigators look for, how to prepare, and how to respond to data integrity observations
Quality, regulatory, IT, and manufacturing professionals responsible for GMP documentation systems, data integrity governance, and electronic records compliance in FDA and EU GMP-regulated environments.
Quality Assurance (QA) Departments
Regulatory Affairs Departments
Manufacturing Operations Departments
Information Technology (IT) & Systems Departments
Quality Control (QC) Departments
Compliance & Validation Departments
Document Control Departments
The pharmaceutical industry's adoption of electronic batch records and digital documentation management systems has accelerated significantly over the past decade. Electronic records offer significant advantages — real-time data capture, automated calculations, reduced transcription errors, and faster batch release cycles. But the regulatory requirements governing these systems have grown correspondingly more demanding.
21 CFR Part 11 has been in force since 1997, yet FDA warning letters citing Part 11 violations continue to be issued with notable regularity. EU GMP Annex 11 was revised in 2011 and continues to be interpreted broadly by EMA investigators. The European Medicines Agency, MHRA, and several other regulatory authorities have issued standalone data integrity guidance documents since 2015, each placing increasing emphasis on the quality and completeness of audit trails, the robustness of access controls, and the ability of regulated organizations to demonstrate the provenance of every GMP record.
Organizations that implement electronic batch record systems without a comprehensive understanding of these regulatory requirements — or that allow documentation practices to evolve organically without structured governance — consistently find themselves facing data integrity observations during regulatory inspections. In some cases, these observations trigger import alerts, consent decrees, and manufacturing suspensions.
This webinar provides the structured regulatory knowledge and practical compliance framework that quality, manufacturing, and IT professionals need to implement, govern, and continuously improve digital documentation systems that are genuinely inspection-ready — not just technically compliant on paper.
John E. Lincoln is an independent pharmaceutical GMP compliance consultant with extensive experience in electronic records management, data integrity governance, and computer system validation for FDA and EU GMP regulated environments. His practice focuses on helping pharmaceutical manufacturers, biotechnology companies, and medical device firms implement and govern digital documentation systems that meet 21 CFR Part 11 and EU GMP Annex 11 requirements.
Mr. Lincoln has supported numerous organizations through FDA pre-approval inspections, routine surveillance inspections, and consent decree remediation programs involving data integrity observations. He has developed data integrity remediation programs, audit trail review SOPs, electronic signature governance frameworks, and computer system validation methodologies for organizations ranging from virtual biotechs to large multinational pharmaceutical manufacturers.
He brings a practical, inspection-informed perspective to all training sessions, with a focus on building documentation compliance programs that are operationally sustainable and genuinely inspection-ready rather than theoretically compliant.
Join this focused 90-minute compliance session on FDA and EU GMP digital documentation, data integrity governance, and electronic records management.